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The therapeutic landscape in rheumatoid arthritis: 
why are antigen-specifi c strategies needed?
Rheumatoid arthritis (RA) is a systemic infl ammatory 
disease resulting from an autoimmune response to self-
antigens, leading to infl ammation of synovial tissue of 
joints and subsequent cartilage and bone erosion. 
Current treatments such as disease-modifying anti-
rheumatic drugs and biologic inhibitors of TNF, IL-6, 
T cells and B cells have dramatically improved the quality 
of life for patients with RA. Th e progressive improvement 
in RA therapy that has occurred since the 1990s results 
from evidence that combination therapy is more eff ective 
than monotherapy, and that better RA outcomes occur 
with early therapeutic intervention and through the 
development and use of biologic therapies [1,2]. However, 
all current treatments are nonspecifi c suppressors of 
infl ammatory pathways or of immune cells and may lead 
to adverse events. Side eff ects of current treatments 
range from peptic ulceration and hepatotoxicity to 
serious life-threatening infections and demyelinating 
disease.
Current drugs do not generally induce long-term drug-
free remission or restoration of immune tolerance to self-
antigens, and lifelong treatment is normally required. 
More over, approximately 30% of RA patients do not 
reach the desired treatment outcome  – due to drug 
failure rates and/or toxicity [3]. For those patients 
experiencing serious adverse eff ects or treatment failure, 
disease progression may lead to deformity, disability and 
loss of productivity [4]. Furthermore, uncontrolled 
infl am mation in RA is associated with a higher risk of 
atherosclerotic disease and cardiac complications with 
increased mortality [5]. Many of the current eff ective 
biologic drugs are very costly to produce in the quantities 
required to meet demand for the drug, placing a heavy 
burden on health authorities, patients and the community 
[6]. Th ere is thus a recognised need for better treatments 
in RA. Ideally these treatments would target underlying 
disease pathogenesis with greater specifi city, producing 
fewer side eff ects.
No therapeutic has yet achieved antigen specifi city for 
controlling symptoms in RA. Th e development of such 
strategies has so far been limited by insuffi  cient know-
ledge of RA autoantigens, of the autoimmune patho gene-
sis of RA and of the mechanisms of immune tolerance in 
man. On the contrary, excellent underpinning knowledge 
of infl ammatory mediators of joint pathology, and the 
potent disease-modifying eff ect and the excellent 
revenues achieved by passive transfer of fully or partly 
humanised antibodies or soluble receptors targeting 
infl ammatory pathways, have stimulated the develop-
ment of many approaches over the past decades to reduce 
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the infl ammatory burden of RA. Th is development has 
improved the therapeutic options available to doctors 
and patients, and has captured a huge market in RA, 
predicted to be $12 billion annually by 2017. Eff ective 
tolerance-inducing antigen-specifi c immunotherapeutic 
strategies hold promise of greater specifi city, of lower 
toxicity and of a longer-term solution to controlling or 
even preventing RA. After decades of disappointing 
results in this area, we are at last moving towards new 
therapeutic possibilities. Th is paper reviews current 
under standing of autoantigens and their relationship to 
immuno pathogenesis of RA, and evolution of thera peutics 
developed to leverage normal tolerance mecha nisms for 
implementation of antigen-specifi c therapy in RA.
Self-reactivity to post-translationally modifi ed 
antigens in RA and its implications for 
immunotherapy
Autoreactivity towards a variety of self-proteins has been 
associated with the development and progression of RA. 
Some of the antigens described are joint-derived 
proteins, such as type II collagen and human cartilage-
derived glycoprotein HCgp39 [7]. Other antigens are 
stress-associated proteins, including grp78/BiP, which is 
an intracellular chaperone involved in endoplasmic 
reticu lum stress and angiogenesis in proliferative RA 
synovial tissue [8,9]. Endoplasmic reticulum stress may 
be provoked by many factors, including proinfl ammatory 
cytokines, cell death, misfolding of proteins in the 
endoplasmic reticulum, and reactive oxygen species [10]. 
As a result of intracellular Ca2+ fl ux in these settings, 
deimination or citrullination of arginine is enhanced 
through activation of the peptidyl arginine deiminase 
enzymes [11]. Owing to the reduction in positive charge, 
citrullination substantially aff ects the protein structure 
and function, for example, of enzymes. Th ese changes 
can aff ect the quality and stiff ness of the extracellular 
membrane at infl amed sites [12].
Citrullination also plays a physiological role in 
apoptosis and epigenetics [13]. Citrullinated self-antigens 
have emerged as a major group of post-translationally 
modifi ed autoantigens in RA. Approximately 70% of RA 
patient sera contain autoantibodies reactive to a variety 
of citrullinated peptide antigens (ACPA) [14]. Th ese 
autoantigens include vimentin, fi brinogen, collagen type 
II, α-enolase, clusterin, histones and peptidyl arginine 
deiminase-4 itself [11,15,16]. Citrullinated self-proteins 
are found in infl amed RA joints, but are not specifi c to 
RA. Post-translationally modifi ed peptides probably 
repre sent an important means to diversify the repertoire 
of antigens (the immunopeptidome), and thus respond-
ing T  cells, in response to infl ammatory or stressful 
priming events such as infections. Smoking is an inducer 
of peptidyl arginine deiminase in the lung, and is likely to 
be a major trigger of post-translational modifi  cation of 
self-antigens in RA, including citrullination [17,18]. Stress-
inducing environmental agents such as smoking, obesity, 
and exposure to toxins such as silica and mineral oils 
promote expression of post-trans lationally modifi ed neo-
antigens, which may trigger priming of autoreactive 
T cells in the peripheral reper toire of individuals geneti-
cally susceptible to RA.
Th e major histocompatibility complex (MHC) contri-
butes about one-third of the genetic susceptibility to RA. 
Specifi c RA-associated human leukocyte antigen (HLA)-
DR alleles encode a conserved amino acid sequence in 
the HLA-DR antigen-binding groove, known as the 
shared epitope (SE) [19]. ACPA – refl ecting autoreactivity 
to citrullinated self-antigens  – are much more likely to 
occur in patients with the HLA-DR SE [20]. Polymor-
phisms at amino acid positions 11, 71 and 74 of the DRβ 
chain and single amino acid associations in the peptide 
binding groove of HLA-B (position  9) and HLA-DPβ1 
(position 9) were found almost completely to explain the 
MHC association with seropositive RA [21]. Amino acids 
at positions 71 and 74 form part of the fourth anchoring 
pocket (P4 of HLA-DR). Th e encoded amino acid at 
position 71 is positively charged, and therefore prefer-
entially binds nonpolar amino acids, including citrulline, 
but not the unmodifi ed positively-charged arginine [21].
It has been proposed that tightly-bound post-
translationally modifi ed peptide antigens are available for 
presen tation to the T-cell antigenic receptor in the 
periphery, but not for negative selection in the thymus 
[22]. Deletion of auto reactive T  cells in the thymus 
depends on strong T-cell receptor (TCR) recognition and 
signalling by peptide-MHC complexes, which would not 
occur with non binding native self-peptides. Peptides 
modifi ed by a variety of post-translational modifi cations, 
including citrulli nation, transglutamination and oxida-
tion, are implicated in a number of autoimmune diseases, 
includ ing multiple sclerosis, type 1 diabetes and coeliac 
disease [23,24]. Post-translational modifi cations are likely 
to represent a general mechanism for immune priming to 
neoself-antigens for which T  cells potentially reactive 
with the native self-antigen were poorly deleted in the 
thymus, if at all, due to insuffi  cient binding strength of 
the native peptide to the susceptibility HLA allele.
Following the initial elucidation of citrullinated T-cell 
epitopes that bound strongly to HLA-SE molecules, and 
which stimulated T-cell responses and infl ammatory 
arthritis in HLA-DR4 transgenic mice [25,26], we and 
others demonstrated citrullinated autoantigen-specifi c 
T-cell autoimmunity in RA patients carrying HLA 
susceptibility alleles [27-29]. We found that proinfl am-
matory cytokines were secreted by peripheral blood (PB) 
CD4+ T  cells of RA patients and healthy controls, in 
response to citrullinated but not unmodifi ed peptides in 
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the context of the HLA-SE sequence. RA patient T cells 
secreted a broader range of cytokines than healthy 
control T  cells. Of the peptides tested, citrullinated 
aggrecan was most immunogenic [27]. Together, these 
studies indicate that citrulline does indeed confer the 
capacity of self-peptides to bind the SE, and that PB 
T  cells from HLA-SE-positive individuals respond to 
these peptides in vitro.
Antigen-specifi c tolerising immunotherapy and 
dendritic cells
Loss of tolerance to self-antigens is a critical component 
in the pathogenesis of autoimmunity. Both central 
(thymic) and peripheral tolerance mechanisms exist for 
the control of self-reactive T cells. Active mechanisms of 
peripheral tolerance include deletion of self-reactive cells 
after antigen recognition and regulation of self-reactive 
eff ector responses by specialised populations of regula-
tory T  cells (Tregs). Th ese mechanisms maintain the 
toler ant state in order to avoid autoimmune disease long 
term. Several T-cell and natural killer T-cell populations 
with the ability to inhibit the response of eff ector T cells 
have been described.
Autoreactivity of T  cells and B  cells towards self-
antigens associated with the development and progres-
sion of RA presents an opportunity for antigen-specifi c 
tolerising immunotherapy to induce antigen-specifi c 
regulatory cells, including Tregs. Attempts to harness 
antigen-specifi c tolerance to modify the autoimmune 
response in RA have been made since the early 1990s. 
Th ese include oral tolerance, TCR peptide vaccination 
and HLA-DR peptide vaccination. Antigens used in oral 
tolerance trials include type II bovine or chicken collagen, 
HCgp39, dnaJp1, and lyophil ised Escherichia coli extract. 
Oral tolerance relies on presentation of the relevant 
peptides by constitutive mucosal dendritic cells (DCs), 
with the capacity to regulate pathogenic T  cells by 
deletion, immune devia tion or through Treg-mediated 
suppression (Figure  1a). While some evidence for 
induction of regulatory populations or immune deviation 
to less pathogenic T-cell cytokines was produced, effi  cacy 
of oral auto antigens was limited [30-32].
Tolerogenic antigen presentation after mucosal delivery 
by mucosal DCs, however, may be unreliable for several 
reasons. First, there may be a small tolerising antigen 
dose window, and disease fl ares may occur due to antigen 
sensitisation of the immune system [33]. Th is is a well-
described side eff ect of specifi c immunotherapy for 
allergic desensitisation, which relies on immune devia-
tion and induction of Tregs to crude allergen preparations 
delivered to the skin or sublingually. Second, the capacity 
of Tregs to suppress pathologic cytokine production by 
eff ector T cells is dysfunctional and DCs are activated at 
infl ammatory sites in RA, and therefore unpredictable 
eff ects may occur without control over the antigen pre-
sent ing cells at mucosal sites [34-37]. Th ird, the gastro-
intestinal tract of RA patients may be colonised with 
distinct microfl ora, including oral Porphyromonas gingi-
valis, which may themselves promote infl ammatory 
arthritis [38]. Finally, eff ector-memory autoreactive 
T  cells  – present in RA synovium  – are known to be 
more resistant to tolerance mechanisms than naïve 
T cells [39,40].
Alternatively, DCs presenting autoantigen in vitro or in 
vivo could be modifi ed to promote their capacity to 
delete antigen-specifi c T  cells or to induce antigen-
specifi c Tregs in vivo: so-called tolerising DCs (Figure 1b). 
Such DCs, when delivered with appropriate autoantigens, 
should aff ord greater control over the outcome of 
antigen-specifi c immunotherapy through the induction 
of Tregs. If this strategy were eff ective, antigen-specifi c 
suppression of pathogenic T  cells in RA patients would 
avoid generalised immune suppression, focusing toler-
ance mechanisms on relevant autoantigens. Th is eff ect 
might be anticipated to restore tolerance towards RA 
self-antigens with low toxicity, suitable for suppression of 
early disease or for prevention in individuals at risk.
Translation of tolerising immunotherapeutic 
approaches in RA and other autoimmune and 
infl ammatory diseases
Oral tolerance
In animal models, orally administered type II collagen 
suppressed collagen-induced arthritis as well as adjuvant 
arthritis  – the latter presumably through secretion of 
anti-infl ammatory cytokines by bystander T  cells, or 
linked suppression through induction of collagen type II-
specifi c regulatory cells and their migration to the joint 
[41-43]. Oral mycobacterial heat shock protein 65 or 
human gp39 also attenuated collagen-induced arthritis 
and adjuvant arthritis [44,45]. Oral chicken or bovine 
type II collagen was safe when administered to patients 
with RA. While some clinical improvement was noted in 
open-labelled studies, placebo-controlled trials found no 
statistically signifi cant improvement in collagen-fed 
patients, including among patients with early RA 
[30,46-48]. Oral human gp39 was also trialled by two 
companies, but with little evidence of effi  cacy [49]. Oral 
lyophilised E. coli extract contains several bacterial heat 
shock proteins with immunomodulatory properties. Th e 
extract’s clinical effi  cacy was equivalent to d-penicil-
lamine in a placebo-controlled trial [50]. However, this 
extract is more likely to be a nonspecifi c immuno-
modulator than to induce antigen-specifi c tolerance.
Oral dnaJp1 was trialled in phase I and phase II clinical 
trials in RA. Th is bacterial heat shock protein sequence 
has been proposed to be cross-reactive with corres pond-
ing self-peptides in RA because it is homologous with the 
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HLA-DR SE sequence. Oral dnaJp1 had an excellent 
safety profi le and demonstrated immune modulatory 
eff ects. Whereas patients generally made Th 1-type T-cell 
cytokine and proliferative responses to dnaJp1 at 
baseline, dnaJ-specifi c proliferation and IFNγ decreased 
and IL-4 and IL-10 increased after the treat ment [51]. In 
a placebo-controlled phase II clinical trial, the dnaJp1-
treated group showed statistically signifi  cant improvement 
in American College of Rheumatology scores after 6 
months of daily oral dnaJp1 peptide, associated with 
increased expression of regulatory molecules and 
decreased secretion of TNF in PB [52].
T-cell receptors in RA and T-cell receptor peptide vaccination
Diversity is generated through gene rearrangement 
within the Variable (V) domains of the TCR; namely, the 
Figure 1. Principles underlying the induction of antigen-specifi c regulation. (a) Mucosal tolerance. Rheumatoid arthritis (RA) self-antigen 
is delivered to the mucosal immune system by the oral or nasal route. If taken up and presented by the appropriate CD103+ dendritic cells (DCs), 
which reside in the transforming growth factor-beta (TGFβ)-rich gut lamina propria and draining lymph nodes, antigen-specifi c regulatory T cells 
(Tregs) can be induced in the presence of all-trans retinoic acid (ATRA). These Tregs should suppress RA self-antigen-specifi c immune responses in 
the joint. (b) Tolerising DC immunotherapy. DCs with tolerising capacity are generated from peripheral blood monocytes in vitro in the presence of 
inhibitory drugs to prevent DC activation after contact with Toll-like receptor ligands or cytokines. The DCs are then exposed to RA self-antigen and 
washed. The antigen-presenting DCs are injected and should induce antigen-specifi c Tregs in draining lymph nodes. These Tregs should suppress 
RA self-antigen-specifi c immune responses in the joint. Tolerizing DC + antigen may also be injected into joints, venous blood or lymphatics. 
Ag, antigen.
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V and Junction gene segments of the Vα chain, and the V, 
Diversity and Junction gene segments of the Vβ chain. 
Junctional diversity also occurs through random 
insertions and deletions at these V–Diversity–Junction 
regions. Th is diversity is manifested in the comple men-
tarity determining regions (CDRs) of the TCR, which 
directly interact with the peptides presented by MHC 
class II (pMHC-II). Despite the potential breadth of the 
TCR repertoire, there are many examples in anti-viral 
immunity of biased or restricted Vα or Vβ usage and 
CDR3 sequences [53]. Th is eff ect is known as a public 
immune response, in which individuals share a similar T-
cell repertoire to a given HLA-restricted peptide antigen. 
Although early studies suggested bias in the T-cell 
repertoire in RA, their interpretation is limited by the 
techniques used [54-56]. More recently, using real-time 
PCR, biased Vβ usage and CDR3 sequences were shown 
in the synovial fl uid T-cell repertoire of RA patients, 
particularly in patients with HLA-DRB1*0405 [57]. 
Furthermore, evidence of T-cell clonal expansion in 
synovial tissue of early RA patients was shown by Vβ 
TCR sequencing. While the most expanded clones were 
shared between diff erent joints, CDR3 sequences were 
not shared between patients [58]. Th is study was 
insuffi  ciently sensitive to address the question of public 
TCR sequences, however, because HLA-DRB1*04 alleles 
were not subtyped to allow comparison of sequences 
associated with a single MHC allele.
An alternative approach to antigen-specifi c vaccination 
is based on evidence from animal models, including 
arthritis and experimental allergic encephalomyelitis, 
that antigen-specifi c T-cell lines or clones prevent 
priming of autoimmune diseases [59]. Th e mechanism of 
this phenomenon was in part related to induction of 
Tregs reactive with the CDR3 regions of the autoreactive 
TCRs [60]. Th e approach has been pursued in a number 
of trials in multiple sclerosis patients. Although modest 
benefi ts have been reported, these are all open-labelled 
studies (reviewed in [61]). Based on some early work 
suggesting that Vβ3, Vβ14 and Vβ17 deter mi nants were 
dominant in RA, a trial was undertaken of Vβ3, Vβ14 and 
Vβ17 peptides emulsifi ed in incomplete Freund’s 
adjuvant [62]. Vaccination with a limited number of 
peptides on a population basis assumes the presence of 
public TCR determinants. Given that patients were not 
recruited on the basis of a defi ned HLA-DR allele (no 
HLA typing was reported), the clinical eff ects of the 
peptide vaccination were predictably small [62].
CD4+CD25+ natural regulatory T cells
Mice thymectomised on day 3 after birth develop a syn-
drome of organ-specifi c autoimmune disease, including 
oophoritis, gastritis, and/or thyroiditis. Th e mice can be 
rescued from illness by transfer of CD4+CD25+ T  cells 
from a syngeneic adult spleen, and depletion of this 
population from nonthymectomised mice leads to a 
similar spectrum of autoimmune disease [63-66]. Since 
these discoveries were made in the 1960s and 1970s, 
CD4+CD25+ Tregs (known as natural Tregs), which ex-
press the transcription factor FoxP3, have been well 
charac terised as a thymic-derived suppressor or regula-
tory population that regulates eff ector T-cell proliferative 
and cytokine responses to self-antigens and foreign 
antigens, innate infl ammatory cells and DCs [67-69]. 
Owing to their high expression of the high affi  nity IL-2 
receptor CD25, they survive and expand in response to 
IL-2 and anti-CD3/CD28 activation in vitro and in vivo 
[70]. Bulk Tregs expanded ex vivo or in vivo (using 
immature DCs), when transferred to mice with collagen-
induced arthritis, slowed the progression of disease in an 
antigen nonspecifi c manner, through local eff ects on the 
joints [71,72]. Autoantigen-specifi c TCR-transgenic Tregs 
expanded using DCs, peptide and IL-2 similarly restored 
normoglycemia to mice with type 1 diabetes [73]. 
Transfer of bulk IL-2-expanded and CD3/CD28-ex-
panded Tregs [74] has been translated to patients with 
type 1 diabetes in a clinical trial, currently underway.
Induced CD4+ regulatory T cells including T regulatory type 
1 cells
T regulatory type 1 (Tr1) cells can be induced in vitro and 
in vivo in the periphery by DCs expressing high levels of 
IL-10 and low IL-12 [75,76]. Tr1 cells secrete high levels 
of IL-10 and moderate levels of transforming growth 
factor-beta, granulocyte–macrophage colony-stimulating 
factor, IL-5 and IFNγ, but little IL-4 [77]. A review article 
describing a phase I clinical trial of IL-10-induced donor 
lymphocytes in patients with high-risk hematopoietic 
malignancies transplanted with CD34+ hemopoietic stem 
cells from haploidentical donors reported mild acute and 
no chronic graft-versus-host disease in patients receiving 
Tr1 cells [78].
Extra-thymic antigen-specifi c FoxP3+ Treg induction or 
conversion from CD4+FoxP3–CD25– naïve T  cells has 
been demonstrated in gut-associated lymphoid tissue 
and mesenteric draining lymph nodes. All-trans retinoic 
acid is a key regulator promoting this conversion, in the 
presence of gut-derived DCs, transforming growth 
factor-beta and antigen [79,80] (Figure 1a). Th e CD103+ 
DC subset, found in gut and mesenteric lymph node, 
plays a specialised role in Treg conversion, as expression 
of aldh1a2  – a retinal dehydrogenase involved in the 
conversion of retinal (vitamin A) into all-trans retinoic 
acid  – is increased in this subset [81,82]. All-trans 
retinoic acid promotes the generation of FoxP3+ Treg in 
the presence of anti-CD3 and in the absence of antigen-
presenting cells, indicating that all-trans retinoic acid 
signals CD25– Treg precursors through a retinoic acid 
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receptor, promoting FoxP3 expression in the presence of 
transforming growth factor-beta [83-85].
Tolerising dendritic cell immunotherapy
Tr1 Tregs can be induced in vivo by NF-κB or CD40-
defi cient DCs. NF-κB is a transcription factor family 
comprising fi ve subunits involved in two pathways: the 
classical pathway (including p65 transcriptional activity) 
plays an important role in innate immunity, and the 
alternate pathway (including RelB activity) plays a role in 
immune tolerance and adaptive immune activation 
[86,87]. RelB activity is required for myeloid DC diff er en-
tiation and function [88-90]. We showed that RelB regu-
lates antigen-presenting cell function through regulation 
of CD40 and MHC molecule expression [91,92]. Antigen-
exposed myeloid DCs, in which RelB function is 
inhibited, prevent priming of immunity and suppress a 
previously-primed immune response. RelB activity thus 
determines the consequences of presentation of antigen 
by myeloid DCs. Induction of suppression was specifi c 
for the antigen to which DCs had been exposed. Th is 
suppression resulted from induc tion in draining lymph 
node and spleen of antigen-specifi c Tregs resembling Tr1 
cells, which were CD4+IL-10+. CD4+ splenic T cells from 
tolerant animals transferred antigen-specifi c tolerance to 
primed recipients. Th e DCs therefore induced an active 
infectious process of antigen-specifi c regulation [93].
We and others have developed other means to block 
production or nuclear translocation of RelB and other 
NF-κB family members in DCs, including anti-sense and 
soluble inhibitors, and the resulting modifi ed DCs were 
consistently tolerogenic through induction of Tregs 
[91,94,95]. Induction of tolerance in response to one 
antigen does not simultaneously produce tolerance to 
antigens expressed elsewhere in the body. Th is property 
allows for exquisite specifi city in tailoring therapeutic 
interventions to specifi c pathogenic antigens without 
global immune suppression. Given the potential for 
development of antigen-specifi c autoimmune immuno-
therapy using DCs treated with soluble inhibitors of 
NF-κB, such as Bay11-7082 (Bay-DCs) [94], we translated 
this concept to a phase I clinical trial of autologous Bay-
DCs exposed to citrullinated peptides in HLA-DR-
SE+ACPA+ RA patients. In vitro studies of human blood 
Bay-DCs demonstrated similar phenotype and in vitro 
functional capacity to murine Bay-DCs [96]. Preclinical 
experiments in the mBSA antigen-induced arthritis 
model demonstrated suppres sion of established arthritis, 
equivalent to treatment with soluble TNF receptor, in 
mice treated with a single dose of Bay-DCs exposed to 
mBSA but not to control antigen. Skin-test reactivity to 
mBSA was simultaneously reduced and anti-mBSA 
antibodies were switched from Th 1 to Th 2 and regulatory 
isotypes, including IgG1 and IgA but not IgE [97]. 
Preliminary clinical data demonstrate the feasibility, 
safety, systemic and clinical eff ects of a single intradermal 
administration of Bay-DCs exposed to citrullinated 
peptides in RA patients [98].
A number of other approaches have been used to 
generate tolerising human or murine DCs from PB or 
bone marrow precursors, based on suppression of DC 
activation in response to infl ammatory stimuli [99]. DCs 
are commonly generated from precursors, and then 
incubated with pathogen-associated molecular pattern 
activators, such as lipopolysaccharide or monophos-
phoryl lipid A, in the presence of NF-κB inhibitors, such 
as vitamin D3, glucocorticoids or IL-10, or the mam-
malian target inhibitor rapamycin. Alternatively, DCs are 
incubated with TNF, IL-6 or low-dose endotoxin to 
produce so-called semi-mature or tolerant DCs [100-
104]. A phase 0 clinical trial of dexamethasone, vitamin 
D3 and monophosphoryl lipid A-modulated autologous 
DCs in RA patients is in progress [104], and interesting 
phase 1 safety, immunological and clinical data from a 
clinical trial of modifi ed autologous DCs in long-standing 
type 1 diabetes patients were recently published [105].
Conclusions and challenges for the fi eld
Restoration of tolerance to self-antigens is currently an 
exciting fi eld. After many years in the doldrums, 
considerable progress has been made to understand how 
T-cell regulation occurs and how to control antigen-
presenting cells for induction of tolerance. Moreover, 
persistent eff orts to translate cellular therapeutic approaches 
from mouse models have seen the commence ment and 
early reporting of data from proof-of-concept clinical 
trials of both tolerising DCs and Treg transfer in auto-
immune disease and graft-versus-host disease.
Th ere are several key challenges. First, personalised 
autologous cell therapy is extremely challenging to 
develop for widespread clinical use. A major challenge 
pertains to the regulatory requirements for standard i-
sation, sterility and quality control of cell therapies. If 
used to obtain PB cells, leukapheresis is associated with a 
degree of morbidity, and is logistically diffi  cult in many 
centres. Th ere are also diffi  culties designing protocols 
with adequate control groups, and as trials continue in 
this area there will be diffi  culties comparing results from 
individual small trials in which varying cell culture 
protocols or antigen preparations have been used. Th e 
cost of carrying out autologous cell therapy trials is also a 
major impediment to the scale-up required for later-
phase trials. Furthermore, this cost may be justifi able in 
cancer settings where therapeutic options are few, but 
this is more diffi  cult in RA.
Clinical trials of various forms of antigen-loaded 
tolerising DCs or antigen-specifi c Tregs will therefore be 
useful to demonstrate proof-of-concept for RA 
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immuno therapy. However, the future challenge is to 
translate such a concept to a therapeutic that is more 
broadly applicable than adoptive transfer of autologous 
cell products. To achieve this challenge, we formulated 
lipo somes to target antigen and NF-κB inhibitor to DCs 
in situ. Curcumin, a natural lipophilic NF-κB inhibitor 
and antioxidant, was incorporated into 400 nm egg 
phosphatidyl choline liposome particles, which were also 
loaded with antigenic proteins or peptides. Th e liposomes 
encapsulated antigens and lipophilic NF-κB inhibitors 
stably and effi  ciently. We injected loaded liposomes into 
mice with antigen-induced infl ammatory arthritis. When 
delivered intravenously or subcutaneously, the liposomes 
targeted antigen-presenting cells including DCs, macro-
phages and B cells in situ, suppressing responsiveness to 
NF-κB and inducing antigen-specifi c Tregs. Th is regu-
latory mechanism suppressed eff ector T-cell responses 
and the clinical signs of full-blown antigen-induced 
arthritis [106]. Th ese results demonstrate that DC func-
tion can be eff ectively altered by NF-κB inhibitors using 
in vivo targeting.
Th e second major challenge is that the diversity of 
autoantigens in RA raises questions about which one(s) 
to target, and whether targeting a single autoantigen 
would fail due to subsequent epitope-spreading in auto-
reactive recipients. Th e mechanism of tolerance induc-
tion is relevant in this regard. Regulatory or suppressive 
T-cell responses targeted to specifi c antigens (antigen-
specifi c Tregs) can simultaneously suppress bystander 
responses in the same location [107]. One might there-
fore anticipate that joint infl ammatory responses might 
be suppressed by arthritogenic antigen-specifi c Tregs of a 
single specifi city even if autoreactivity to multiple auto-
antigens were present. On the contrary, tolerance elicited 
by deletion or anergy of antigen-specifi c T cells would be 
particularly prone to failure, when autoreactive T cells of 
new auto antigenic specifi cities are induced by epitope 
spreading [108]. Th is issue brings perhaps the key 
challenge to the fore: the need for eff ective reagents to 
detect and measure the responses of autoantigen-specifi c 
CD4+ T cells in RA.
Th e development of multimeric pMHC complexes has 
revolutionised the detection of antigen-specifi c T cells in 
mice and humans. Tetramer or multimer reagents consist 
of four or more soluble MHC molecules each loaded with 
a single peptide bound to streptavidin and coupled to a 
fl uorescent marker. By mimicking pMHC complexes 
normally expressed by antigen-presenting cells, tetramers 
bind to the receptors of antigen-specifi c T cells and allow 
them to be enumerated and functionally characterised or 
expanded. pMHC-I tetramers have greatly enhanced 
understanding of the CD8 T-cell response in viral 
infections and cancer. However, stable and specifi c 
pMHC-II tetramer production is technically more 
challenging. Nevertheless this technology has recently 
improved for the production of pMHC-II (human HLA-
DR) tetramers, facilitating the understanding of auto-
immune responses [109]. Low-frequency antigen-specifi c 
T-cell populations have been identifi ed in the blood of 
patients with coeliac disease and type 1 diabetes, and 
analysis of the TCR repertoire can greatly enhance 
understanding of the way that post-translationally 
modifi ed peptides may be driving autoimmune disease 
processes [110]. Although it is clear that ACPA are highly 
specifi c for RA, the understanding of T-cell responses 
towards such autoantigens in RA is still rudimentary. 
Ongoing development of a toolkit of more sensitive 
pMHC-II tetramer biomarkers, so that autoantigen-
specifi c T-cell responses can be monitored during clinical 
trials of antigen-specifi c therapy, is clearly essential for 
ongoing development in this fi eld.
ACPA may predate the onset of clinical RA by up to 
15 years [111]. Addition of assays for rheumatoid factor 
isotypes and for multiple serum cytokines and chemo-
kines has been shown to enhance the specifi city for 
prediction of RA disease onset [16,112]. Th ese advances 
in biomarkers for prediction of future disease, as well as 
evidence that treatment of patients with undiff erentiated 
arthritis may delay the diagnosis of RA, suggest that 
preventive approaches might eventually be feasible in 
genetically at-risk individuals or families [113,114]. 
Clearly, demonstration of safety and effi  cacy using 
antigen-specifi c immunotherapeutic strategies in patients 
with early established RA would be an important fi rst 
step along that road.
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